Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

- Approval is based on COSMIC-311 trial, in which CABOMETYX demonstrated significant improvement in progression-free survival versus placebo - Exelixis, Inc. (Nasdaq: EXEL) today announced that

Related Keywords

Iceland ,Norway ,Japan ,United States ,Liechtenstein ,American ,Susan Hubbard ,Vickil Goodman ,Lindsay Treadway ,Daiichi Sankyo Company ,European Commission ,Drug Administration ,Genentech Inc ,Bristol Myers Squibb Company ,Takeda Pharmaceutical Company ,Nasdaq ,Exchange Commission ,Product Development ,Exelixis Inc ,Public Affairs ,European Union ,Facebook ,American Cancer Society ,Executive Vice President ,Medical Affairs ,Chief Medical Officer ,Takeda Pharmaceutical Company Limited ,Hypertensive Crisis ,Plantar Erythrodysesthesia ,Impaired Wound Healing ,Posterior Leukoencephalopathy Syndrome ,Fetal Toxicity ,Prescribing Information ,Standard Poor ,Exelixi Annual Report ,Bristol Myers Squibb ,Cancer Journal For ,About Thyroid ,Accessed May ,Adv Med ,Rev Endocrinol ,Clin Endocrinol ,Advocacy Relations ,Exelixis ,Partner ,Apsen ,Eceives ,European ,Commission ,Approval ,Cabometyx ,Cabozantinib ,Patients ,Reviously ,Reated ,Radioactive ,Iodine ,Refractory ,Differentiated ,Thyroid ,Dancer ,